Effects of Omega-3 Polyunsaturated Fatty Acids on Heart Function and Oxidative Stress Biomarkers in Pediatric Patients with Dilated Cardiomyopathy

Omidreza Firuzi¹, Nader Shakibazad², Hamid Amoozgar²,³*, Mohammad Borzoei², Saeed Abtahi², Gholamhossein Ajami², Pegah Ardi¹, Ramin Miri¹

¹ Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
² Division of Pediatric Cardiology, Department of Pediatrics, Shiraz University of Medical Sciences, Shiraz, IR Iran
³ Cardiovascular Research Center, Shiraz University of Medical Science, Shiraz, IR Iran

ARTICLE INFO

Article Type: Research Article

Article History:
Received: 7 Dec 2012
Revised: 5 Jan 2013
Accepted: 13 Feb 2013

Keywords:
Dilated Cardiomyopathy
Polyunsaturated Fatty Acid
Omega-3

ABSTRACT

Objectives: Dilated cardiomyopathy is the most prevalent type of cardiomyopathy in children, which results in congestive heart failure and causes significant morbidity and mortality. This study, aims to investigate the effect of supplementation with omega-3 polyunsaturated fatty acids (n-3 PUFA) on heart function and oxidative stress biomarkers in these patients.

Methods: The present research was a case-control study on pediatric patients with dilated cardiomyopathy, who received n-3 PUFA and anti-failure therapy for 6 months (group 1, n = 6), or anti-failure therapy alone for 6 months (group 2, n = 6), as well as age matched normal individuals (group 3, n = 6), and evaluated the cardiac function and biomarkers of oxidative stress.

Results: Echocardiographic parameters, such as left ventricular ejection fraction, shortening fraction, tissue Doppler Ea and Aa waves of lateral annulus of tricuspid valve, and Ea and S wave of septum, were significantly improved in group 1 after n-3 PUFA compared to pre-treatment status, while they were not changed after treatment in group 2. Antioxidant enzymes, including catalase and glutathione peroxidase activities in erythrocytes were slightly decreased, while plasma 8-iso-prostaglandin F2α concentrations were somewhat increased in group 1 compared to groups 2 and 3, however these changes were not statistically significant. Total antioxidant capacity of plasma was similar in all 3 groups.

Conclusions: The results indicate that some echocardiographic parameters were significantly improved in patients receiving omega-3 fish oil. However, omega-3 had no significant effect on oxidative stress biomarkers.

Implication for health policy/practice/research/medical education: This study is implicated in management of heart failure in children.

Please cite this paper as:
Firuzi O, Shakibazad N, Amoozgar H, Borzoei M, Abtahi S, Ajami G, Ardi P, Miri R. Effects of Omega-3 Polyunsaturated Fatty Acids on Heart Function and Oxidative Stress Biomarkers in Pediatric Patients with Dilated Cardiomyopathy. Int Cardivasc Res J. 2013;7(1):8-14.

1. Background

Dilated cardiomyopathy (DCMP) is a disorder of cardiac muscle and is characterized by a dilated ventricular chamber, mainly left ventricle and systolic dysfunction, which results in congestive heart failure (CHF) and causes significant morbidity and mortality (1-3). DCMP is the most prevalent type of cardiomyopathy in children that commonly leads to cardiac transplantation in adults and children (2,4). Towbin and co-workers have reported the...
incidence of DCMP in pediatric age group as 0.57 cases per 100,000 per year. They also stated that the incidence of the disorder was higher in boys than in girls and the disease was more prevalent in infants less than 1 year-old compared to the older children (4).

Primary DCMP is either acquired or occurs as a result of genetic trait. Familial type of DCMP develops in 20-50% of the cases and autosomal-dominant inheritance is more prevalent compared to X-linked, autosomal recessive, and mitochondrial inheritance. Acquired primary disease can be secondary to inflammatory diseases, such as myocarditis, or due to a large number of systemic causes (1,2). Echocardiography is an excellent non-invasive method for detecting DCMP in children (4-7). The principle in treatment of dilated cardiomyopathy is mainly directed toward reducing the heart-failure symptoms and preventing the disease progression as well as the related complications, such as stroke (2).

Reactive oxygen species including free radicals like hydroxyl radical and superoxide anion and non-radical species such as hydrogen peroxide may play a major role in oxidative stress-related disorders, including cardiovascular diseases (8,9). This has led to the hypothesis that antioxidants can be used as an efficient means of prevention and perhaps treatment of coronary artery diseases, stroke, and peripheral vascular disorders (10). Epidemiological studies support the notion that antioxidants can prevent certain diseases including cardiovascular diseases (11). Some interventional trials have failed to show beneficial effects of antioxidants, but the use of efficient antioxidants in carefully chosen patients with high levels of oxidative stress can probably provide valuable therapeutic tools (10,12).

Omega-3 polyunsaturated fatty acid (n-3 PUFA) including Eicosapentaenoic acid acid and docosahexaenoic acid have recently been used for many medical purposes and may have several applications including lowering the risk of cardiovascular diseases (13-16). The exact mechanisms, which prevent the progression of heart failure by n-3 PUFA, are not well defined. Nevertheless, suppression of inflammatory response and increased secretion of adiponectin by these antioxidant supplements could prevent the left ventricular dysfunction as well as heart failure (17-20).

Several studies have been conducted to assess the effect of n-3 PUFA on heart failure (20,21) and other heart diseases in adults (22). However, limited studies have been performed on children with heart diseases.

The aim of the present study was to determine the effect of n-3 PUFA on heart function parameters and oxidative stress biomarkers in pediatric patients with DCMP.

2. Materials and Methods
2.1 Subjects and treatments
This case-control study recruited 18 individuals from subjects, referred to Namazi hospital, affiliated to Shiraz University of Medical Sciences Shiraz, IR Iran. Three groups of the study consisted of 6 pediatric patients diagnosed with DCMP, who received n-3 PUFA and anti-failure therapy for 6 months (group 1), 6 DCMP patients receiving anti-failure therapy and vitamin (vitamin AandD) (group 2), and 6 healthy volunteers with the same age as the patients in group 1 who received only daily vitamin (group 3).

The clinical and echocardiographic features of the patients were compared in order to evaluate the effect of n-3 PUFA on the heart function of these patients. All echocardiographies were done by a pediatric cardiologist who blinded to groups and the fish oil was supplied by a nurse who was blinded to result of clinical and para-clinical data.

The study was approved by the Ethics Committee of Shiraz University of Medical Sciences, Shiraz, IR Iran and was in accordance with the guidelines of the declaration of Helsinki. Written informed consents were obtained from the patients’ guardians.

2.2 Fish Oil and vitamin
Seven Seas fish oil syrup (Seven Seas, Pure Cod Liver Oil, Seven Seas Ltd, UK) was used in the present study. According to the supplement information sheet, every 10 ml Seven Seas consists of 9.2 g of cod liver oil, 828 mg of eicosapentaenoic acid, 736 mg of docosahexaenoic acid, 4000 IU of vitamin A, 400 IU of vitamin D, and 10 IU vitamin E. The fish oil (170 mL per bottle) was given to the patients of group 1 at the beginning of the study for 6 months and at the monthly follow-up visits. Parents were instructed to give 0.5 mL/kg/day Seven Seas once a day to their children. They were asked to bring the bottles back at each follow-up visit. The amount of fish oil remaining in the bottle was checked and a further supply was given monthly.

All children in groups 2 and 3 received 400 units vitamin D and 4000 units vitamin A as recommended by World Health Organization.

2.3 Blood samples
Blood samples were collected after aforementioned procedures by venipuncture in vacutainers containing EDTA and immediately placed on melting ice. Plasma was separated not later than 2 hours after sample collection. Half of each blood sample was centrifuged at 1500 ×g for 15 min and the plasma was separated and immediately stored at -80 °C. For determination of 8-iso-prostaglandin F2α (iPF2α), 1 μL of butyldihydroxytoluene (BHT) 10 mM was added to each 100 μL of the plasma before dividing it into aliquots. Also some of plasma was used to determine ferric reducing antioxidant power (FRAP) value. The second half of each blood sample was centrifuged at 3000 ×g for 10 min for separation of erythrocytes. The red blood cells were washed 3 times with 0.9% normal saline and then lysed with 5 volumes of deionized ice-cold water, distributed into several small vials, and stored at -80°C for determination of hemoglobin, antioxidant enzymes activities including catalase and erythrocyte glutathione peroxidase (GPX).

2.4 Reagents
Drabkin’s reagent, ethylenediaminetetraacetic acid (EDTA), ferric chloride (FeCl3), glutathione (GSH),
2.5 Echocardiographic methods

Echocardiographic measurements were performed at the beginning and in the end of the study in groups 1 and 2. Echocardiography was performed with a GE Vivid 3 echocardiographic machine (GE Vingmed, Horten, Norway) using a 3-MHz probe with pulsed Doppler tissue imaging software. All M-mode, two-dimensional, Doppler, and pulsed tissue Doppler echocardiographic studies were conducted, with the patient in left lateral decubitus position by the same qualified cardiologist. Ejection fraction, shortening fraction, and septal and posterior wall thickness in systole and diastole were measured in the left parasternal long axis view. The pulsed Doppler sample volume was placed at the mitral valve and tricuspid tips and three cardiac cycles were recorded from the apical window. Early (E) and late (A) peak velocities (m/s) and their ratio were determined to evaluate the diastolic function. Pulsed tissue Doppler images were obtained with the sample volume placed at the lateral corner of the mitral annulus, at the medial (or septal) and tricuspid corner in the apical four-chamber view, and then at the anterior and posterior walls in the parasternal short-axis view. In each region, systolic (S) wave and early diastolic (Ea) as well as late diastolic (Aa) velocities were recorded along with an average of three successive waves.

2.6 Determination of catalase activity of erythrocytes

Erythrocyte catalase activity was spectrophotometrically determined (23). The assay was based on determination of the hydrogen peroxide decomposition in the presence of catalase in erythrocytes by measuring the absorbance change at 240 nm. The final reaction mixture (3.0 mL) contained 2.8 mL of sodium phosphate buffer 50 mM pH 7.2, 100 μL of hemolysate diluted with deionized water (1:3), and 100 μL of hydrogen peroxide 30 mM. The absorbance was determined by a spectrophotometer after 1 min. Proper blank samples were run in parallel. Each unit of catalase activity is defined as the amount of the enzyme required to decompose 1 μmole of hydrogen peroxide (ε = 43.6). For normalization of results, Hemoglobin levels in RBCs lysate measured using the Drabkin’s reagent.

2.7 Determination of glutathione peroxidase activity in erythrocytes

GPX activity in erythrocytes was measured using the Paglia and Valentine method (24) in which the oxidation of glutathione and subsequent production of GSSG (oxidized glutathione) by GPX enzyme is coupled to the oxidation of NADPH by glutathione reductase (GSSG-R). The oxidation of NADPH is followed spectrophotometrically at 340 nm and the rate of its decay was directly considered proportional to the level of GPX enzyme. The reaction mixture contained 50 μL of the hemolsate diluted (1:1), with Drabkin’s reagent, 2.58 mL of potassium phosphate buffer 50 mM (pH 7, EDTA 5 mM), 100 μL of NADPH 2.9 mM, 6.4 μL GSSG-R 455 U/mL, 10 μL of sodium azide 290 mM, and 100 μL glutathione 58 mM. The reaction was started by adding 100 μL of tert-butyl hydroperoxide 17.4 mM. Appropriate Proper blank samples were also run in parallel. The absorbance at 340 nm was measured spectrophotometrically every min for 5 min. In addition, the oxidation of NADPH was determined by using a molar extinction coefficient of 6.22 x 103 Cm-1 M-1 at 340 nm. One unit of GPX activity is defined as the amount of the enzyme required for oxidizing 1 μmole of NADPH per minute.

2.8 Determination of total antioxidant activity of plasma by FRAP assay

Ferric reducing antioxidant power (FRAP) assay was performed according to the method of Benzie and Strain (25) with minor modifications (26). FRAP solution was prepared by mixing 10 mL of acetate buffer 300 mM, pH 3.6, 1 mL of ferric chloride hexahydrate 20 mM in distilled water, and 1 mL of 2,4,6-tris (2-pyridyl)-s-triazine 10 mM in HCl 40 mM. Ten μL of plasma was mixed with 190 μL of FRAP solution in 96-well microplates in duplicate, along with one blank for each plasma sample. The absorbance was measured at 595 nm after 30 min of incubation at room temperature by a microplate reader. FRAP value of the plasma samples were calculated in reference to quercetin, an antioxidant flavonoid, which was tested at a 2.8 Determination of total plasma level of 8-isoprostaglandin F2α (iPF2α)

The level of 8-iso-Prostaglandin F2α (iPF2α), an important index of lipid peroxidation, was determined by an EIA Kit. Briefly, 40 μL of plasma was incubated with 40 μL KOH (15 %) in the dark at 40 C temperature of for 1 hour to hydrolyze the esterified forms of iPF2α. This was then supplemented with 80 μL of ethanol 30% containing 0.01% butyl hydroxytoluene (BHT). After 5 minutes incubation at 4 C, the mixture was centrifuged at 3000 x g for 10 min. The pH of the supernatant fluid was adjusted to 7 by a solution of KH2PO4 1.25 M. The mixture was then diluted by the kit assay buffer (750 μL), and iPF2α level was determined by a commercially available kit. (8-isoprostane EIA Kit at www. www.caymanchem.com )

2.10 Statistical analysis

The comparisons between the study groups were made by ANOVA one-way analysis of variance. Moreover, Mann–Whitney and Kruskal-Wallis tests were used to compare
the non-parametric variables. The data were expressed as mean ± standard deviation. All statistical analyses were performed by SPSS statistical software for Windows (version 16).

3. Results

At the beginning of the study, the mean ages of the patients in groups 1, 2, and 3 were 7.5 (range 3-56), 8 (range 5-47), and 7.8 (range 3-58) months, respectively. In addition, the respective mean weight of group 1 at the beginning and at the end of the study was 6.3±5.2 kg and 9.4±6.3 kg (*P*=0.37). The mean weight of group 2 at the beginning of the study was 7.1 ±6.7 kg, and at its end was 8.0±7.8 kg (*P*= 0.83). Besides, the mean weight of the third group was 8.1 ± 7.3 kg. There were 3 males and 3 females in each group. The mean of weight gain in groups 1 was 2.3±1.3 and in group 2 it was 1.7±1.1 (*P*=0.40).

3.1 Echocardiographic and tissue Doppler parameters

M-Mode echocardiographic parameters including ejection fraction EF, shortening fraction SF, and left ventricle end diastolic dimension were performed at the beginning and at the end of the study in groups 1 and 2 and summarized in Table 1. Doppler indexes of early diastolic (E) wave and atrial contraction (A) wave velocity of Mitral and Tricuspid Valve were also summarized in Table 1.

Finally, tissue Doppler indexes of lateral annular velocity of mitral and tricuspid valve as well as septal waves were measured and demonstrated in Table 2.

3.2 Biomarkers of oxidative stress

Activities of antioxidant enzymes, including catalase and GPX were measured in erythrocytes, while FRAP and iPF2α were determined in plasma of the subjects of three groups at the end of the study (Table 3). Catalase and GPX activities in group 1 (n-3 PUFA plus anti-failure therapy) was decreased compared to group 2 (anti-failure therapy) and group 3 (normal control). However, these changes were not statistically significant. FRAP values did not show any considerable change among the 3 groups. Plasma iPF2α levels were increased in group 1 compared to groups 2 and 3, which were not statistically significant (Table 3).

4. Discussion

Echocardiographic findings in group 1 showed improvement in several parameters after fish oil supplementation compared to before treatment, whereas the group 2 which only received anti failure therapy did not show any significant change after treatment. Oxidative stress biomarkers did not show any significant alteration in any of the 3 groups.

The main therapeutic goal in children with DCMP is to avoid heart transplant and early death. These goals can be achieved by early diagnosis, risk assessment, and application of new therapies, including dietary modification, anticongestive agents, angiotensin-converting enzyme inhibitors, and antiarrhythmic agents (4). In addition, fish oil is known to have beneficial effects

---

**Table 1:** M-Mode Echocardiographic Parameters: EF, SF, LVEDD and Doppler Indices of A and E Wave Velocity of Mitral and Tricuspid Valves

| variable | Group 1 | *P* value within group 1 | Group 2 | *P* value within group 2 | *P* value within groups |
|----------|---------|--------------------------|---------|--------------------------|------------------------|
| EF       | (1) 31.63 ± 9.30 % | 0.01 | 45.75 ± 14.14 % | 0.35 | 0.1 |
| SF       | (2) 39.17 ± 13.76 % | 0.01 | 40.50 ± 14.03% | 0.84 | 0.1 |
| LVEDD    | (1) 4.13 ± 0.80 Cm | 0.1 | 4.23 ± 0.68 Cm | 0.1 | 0.1 |
| E (MV)   | (2) 4.14 ± 0.90 Cm | 0.1 | 4.43 ±0.83 Cm | 0.1 | 0.1 |
| A (MV)   | (1) 1.12 ± 0.35 m/s | 0.1 | 0.96 ± 0.26 m/s | 0.1 | 0.1 |
| E/A (MV) | (2) 1.13 ± 0.24 m/s | 0.1 | 0.98 ± 0.21 m/s | 0.1 | 0.1 |
| E (TV)   | (1) 0.84 ± 0.29 m/s | 0.89 | 0.83 ± 0.37 m/s | 0.77 | 0.76 |
| A (TV)   | (2) 0.82 ± 0.21 m/s | 0.89 | 0.77 ± 0.34 m/s | 0.77 | 0.76 |
| E/A (TV) | (1) 1.38± 0.36 | 0.23 | 1.25± 0.30 | 0.54 | 0.96 |
| E (TV)   | (2) 1.40± 0.23 | 0.23 | 1.39 ± 0.45 | 0.54 | 0.96 |
| A (TV)   | (1) 0.78 ± 0.21 m/s | 0.63 | 0.99 ± 0.24 m/s | 0.23 | 1.0 |
| A (TV)   | (2) 0.85 ± 0.28 m/s | 0.63 | 0.85 ± 0.12 m/s | 0.23 | 1.0 |
| E/A (TV) | (1) 0.54 ± 0.10 m/s | 0.97 | 0.80 ± 0.30 m/s | 0.72 | 0.56 |
| E/A (TV) | (2) 0.55 ± 0.72 m/s | 0.97 | 0.74 ± 0.28 m/s | 0.72 | 0.56 |

(1), Beginning of the study; (2), End of the study

Abbrevations: EF, Ejection Fraction; SF, Shortening Fraction; LVEDD, Left Ventricle End Diastolic Dimension; E, Early diastolic; MV, wave velocity of Mitral Valve; A, Atrial Contraction; E/A, E wave velocity to A wave velocity ratio; TV, Tricuspid Valve.
on cardiovascular diseases in adults (20,21,27); however, few studies have addressed the effect of fish oil on children with DCMP (28).

Our study showed that fish oil treatment in group 1 increased left ventricular ejection fraction (EF) compared to the same patients before treatment. Olgar and colleagues (28) conducted a study on the effect of fish oil on idiopathic DCMP in children and suggested that fish oil supplementation led to accelerated improvement of left ventricular function. In their study, left ventricular EF and left ventricular SF were significantly increased by 8.44±3.80 % and 6.04±4.86 %, respectively, while left ventricular end-diastolic dimension was decreased by 4.36±4.86 mm (P<0.05). This finding suggests that fish oil may accelerate the improvement in left ventricular function, which might be affected by antiatherogenic, antithrombotic, anti-inflammatory, and antiarrhythmic effects of n-3 PUFA. In addition, it has been demonstrated that fish oil decreases the mortality rate, creatine kinase levels, myocardial lipid peroxides, and glutathione levels in experimental myocardial infarction induced by isoproterenol (28). However, in study by Rizos EC et al. in Greece, omega-3 supplementation was not associated with reduction in the risk of cardiovascular mortality, sudden death, myocardial infarction, or stroke (29).

In our study, the lateral tricuspid valve annular velocities in tissue Doppler (S wave, Ea and Aa waves) were measured and showed a significant increase in Ea and Aa waves in the DCMP patients during the follow up (P<0.05); however, they did not show any significant changes in group 2 patients who did not receive fish oil which indicates that n-3 could improve the diastolic function. The same significant improvement was seen in Ea wave and S wave velocities of septum in group 1. S wave velocity of septum was significantly increased in group 1, which might favour the increased systolic function in the fish oil-treated group.


table 2: Tissue Doppler Indices of Lateral Annular Velocity of Mitral and Tricuspid Valves and Septum

| Variables | Group 1 | P value within group 1 | Group 2 | P value within group 2 | P value Between groups |
|-----------|---------|-----------------------|---------|-----------------------|-----------------------|
| Ea Mitral Annulus | (1) 6.45 ± 2.76 cm/s | 0.09 | 10.53 ± 4.94 cm/s | 0.90 | 0.59 |
| Aa Mitral Annulus | (2) 5.96 ± 3 cm/s | | 10.87 ± 4.99 cm/s | | 0.60 | 0.38 |
| Sa Mitral Annulus | (1) 6.45 ± 2.42 cm/s | 0.56 | 8.67 ± 3.66 cm/s | 0.88 | 0.69 |
| Ea Tricuspid Annulus | (2) 7.17 ± 1.74 cm/s | 0.88 | 5.87 ± 1.62 cm/s | 0.70 | 0.50 |
| Aa Tricuspid Annulus | (1) 5.73 ± 1 cm/s | | 6.09 ± 1.92 cm/s | | 0.83 | 0.69 |
| Sa Tricuspid Annulus | (2) 11.73 ± 4.75 cm/s | 0.008 | 14.37 ± 1.65 cm/s | 10.77 ± 3.14 cm/s | 0.89 | 0.06 |
| Ea Septum | (1) 16.52 ± 5.17 cm/s | 0.01 | 14.89 ± 2.86 cm/s | | |
| Aa Septum | (2) 11.51 ± 4.16 cm/s | | 10.08 ± 2.61 cm/s | | |
| Sa Septum | (1) 14.94 ± 2.54 cm/s | 0.75 | 8.99 ± 2.79 cm/s | | |
| (2) 10.11 ± 2.69 cm/s | | 8.52 ± 2.23 cm/s | | |
| (3) 10.6 ± 3.46 cm/s | | 8.17 ± 2.39 cm/s | | |
| (4) 7.82 ± 3.07 cm/s | | 8.17 ± 2.39 cm/s | | |
| (5) 10.65 ± 3.11 cm/s | | 8.17 ± 2.39 cm/s | | |
| (6) 7.44 ± 2.13 cm/s | | 8.17 ± 2.39 cm/s | | |
| (7) 7.23 ± 2.65 cm/s | | 8.17 ± 2.39 cm/s | | |
| (8) 5.10 ± 0.81 cm/s | | 8.17 ± 2.39 cm/s | | |
| (9) 6.21 ± 0.50 cm/s | | 8.17 ± 2.39 cm/s | | |

(1), Beginning of the study; (2), End of the study
Abbrevations: Aa, Tissue Doppler atrial wave velocity; Ea, tissue Doppler early diastolic wave velocity; Sa: Systolic Wave velocity

Studies on hypercholesterolemia (33) and normocholesterolemic (34) subjects have shown that n-3 PUFA supplementation increases plasma malondialdehyde (MDA), a marker of lipid peroxidation. Also exercise-induced increase of MDA has been greater in judo athletes supplemented with n-3 PUFA compared to placebo (35). A large dietary intervention study in subjects with metabolic syndrome (LIPGENE study) (36), and also another research performed on healthy women (37) supplemented with n-3 PUFA, did not show any change in urinary levels of MDA.
of IPF2α. Similarly, acute supplementation of fish oil had no effect on lipid hydroperoxides and oxidized low density lipoprotein in obese men (37). The report of Carrepeiro and colleagues (33) shows that n-3 PUFA reduce catalase expression in women, while other reports on chronic renal failure patients with dyslipidemia showed increased serum Catalase, superoxide dismutase and glutathione peroxidase activities (38).

Our results were in agreement with findings of KANWU study on total antioxidant capacity performed on 162 participants, (31) who received n-3 PUFA for 3 months, as well those reported on obese men (37), receiving an acute supplementation of n3-PUFA, where there were no significant changes in the plasma total antioxidant activity.

5. Conclusion
The results of the present study showed that some echocardiographic parameters, such as left ventricular EF, SF, Ea, Aa waves of lateral annulus of tricuspid valve and Ea wave and S wave of septum were significantly improved in omega-3 fish oil receiving group. However, omega-3 had no statistically significant effect on oxidative stress biomarkers.

Limitations
The small sample size and a short-term follow-up of the patients means that our findings should be interpreted with due caution, and therefore more studies with larger series of patients are needed for better evaluation of this supplement in children.

Acknowledgements
The data presented in this article are part of Dr. Saeed Abtahi’s thesis on specialization in pediatrics. This study was supported by Shiraz University of Medical Sciences, Cardiac research center and neonatology research center.

Financial Disclosure
None declared.

Funding/ Support
This work was financially supported by vice- chancellor of research of Shiraz University of Medical Sciences, under grant number 1699.

References
1. Burkett EL, Hershberger RE. Clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol. 2005;45(7):969-81.
2. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296(15):1867-76.
3. Chen SC. Echocardiography of dilated cardiomyopathy in children. Echocardiography. 1991;8(3):207-17.
4. McMahan CJ, Naguée SF, Eapen RS, Dreyer WJ, Finkelshyn I, Cao X, et al. Echocardiographic predictors of adverse clinical events in children with dilated cardiomyopathy: a prospective clinical study. Heart. 2004;90(8):908-15.
5. Thomas DE, Wheeler R, Yousef ZR, Masani ND. The role of echocardiography in guiding management in dilated cardiomyopathy. Eur J Echocardiogr. 2009;10(8):6-21.
6. Ide T, Tsutsui H, Kinagawa S, Suematsu N, Hayashidani S, Ichikawa K, et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res. 2000;86(2):152-7.
7. Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol. 2005;3(3):221-9.
8. Wilcox BJ, Curb JD, Rodriguez BL. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am J Cardiol. 2008;101(10A):75D-86D.
9. Huxley RR, Neil HA. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr. 2003;57(8):904-8.
10. Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. Curr Med Chem. 2011;18(25):3871-88.
11. Holub BJ. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. CMAJ. 2002;166(5):608-15.
12. Mozaffarian D. Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death. Am J Cardiol. 2008;101(7):915.
13. Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. Curr Med Chem. 2011;18(25):3871-88.
14. Mozaffarian D, Wu JH. (n-3) fatty acids in cardiovascular disease. Prog Lipid Res. 2011;50(4):372-87.
15. Duda MK, O'Shea KM, Lei B, Barrows BR, Azimzadeh AH, McElfresh TE, et al. Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res. 2007;76(2):303-10.
16. Duda MK, O'Shea KM, Stanley WC. Omega-3 polysaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res. 2009;84(1):33-41.
17. Duda MK, O’Shea KM, Tintinu A, Xu W, Khairallah RJ, Barrows BR, et al. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res. 2009;81(2):319-27.
18. Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana McMahon CJ, Nague SF, Eapen RS, Dreyer WJ, Finkelshyn I, Cao X, et al. Echocardiographic predictors of adverse clinical events in children with dilated cardiomyopathy: a prospective clinical study. Heart. 2004;90(8):908-15.
19. Thomas DE, Wheeler R, Yousef ZR, Masani ND. The role of echocardiography in guiding management in dilated cardiomyopathy. Eur J Echocardiogr. 2009;10(8):6-21.
20. Ide T, Tsutsui H, Kinagawa S, Suematsu N, Hayashidani S, Ichikawa K, et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res. 2000;86(2):152-7.
21. Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol. 2005;3(3):221-9.
22. Wilcox BJ, Curb JD, Rodriguez BL. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am J Cardiol. 2008;101(10A):75D-86D.
23. Huxley RR, Neil HA. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr. 2003;57(8):904-8.
24. Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. Curr Med Chem. 2011;18(25):3871-88.
25. Holub BJ. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. CMAJ. 2002;166(5):608-15.
26. Mozaffarian D. Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death. Am J Cardiol. 2008;101(7):915.
27. Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. Curr Med Chem. 2011;18(25):3871-88.
28. Mozaffarian D, Wu JH. (n-3) fatty acids in cardiovascular disease. Prog Lipid Res. 2011;50(4):372-87.
29. Duda MK, O'Shea KM, Lei B, Barrows BR, Azimzadeh AH, McElfresh TE, et al. Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res. 2007;76(2):303-10.
30. Duda MK, O’Shea KM, Stanley WC. Omega-3 polysaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res. 2009;84(1):33-41.
31. Duda MK, O’Shea KM, Tintinu A, Xu W, Khairallah RJ, Barrows BR, et al. Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res. 2009;81(2):319-27.
32. Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana McMahon CJ, Nague SF, Eapen RS, Dreyer WJ, Finkelshyn I, Cao X, et al. Echocardiographic predictors of adverse clinical events in children with dilated cardiomyopathy: a prospective clinical study. Heart. 2004;90(8):908-15.
33. Thomas DE, Wheeler R, Yousef ZR, Masani ND. The role of echocardiography in guiding management in dilated cardiomyopathy. Eur J Echocardiogr. 2009;10(8):6-21.
34. Ide T, Tsutsui H, Kinagawa S, Suematsu N, Hayashidani S, Ichikawa K, et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res. 2000;86(2):152-7.
35. Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol. 2005;3(3):221-9.
36. Wilcox BJ, Curb JD, Rodriguez BL. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am J Cardiol. 2008;101(10A):75D-86D.
37. Huxley RR, Neil HA. The relation between dietary flavonol intake and coronary heart disease mortality: a meta-analysis of prospective cohort studies. Eur J Clin Nutr. 2003;57(8):904-8.
38. Firuzi O, Miri R, Tavakkoli M, Saso L. Antioxidant therapy: current status and future prospects. Curr Med Chem. 2011;18(25):3871-88.
39. Holub BJ. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. CMAJ. 2002;166(5):608-15.
40. Mozaffarian D. Fish and n-3 fatty acids for the prevention of fatal coronary heart disease and sudden cardiac death. Am J Cardiol. 2008;101(7):915.
22. Kumar S, Sutherland F, Wheeler M, Heck PM, Lee G, Teh AW, et al. Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial mechanical function after reversion of atrial arrhythmias to sinus rhythm: reversal of tachycardia-mediated atrial cardiomyopathy with fish oils. *Heart Rhythm*. 2011;8(5):643-9.

23. Aebi H. Catalase in vitro. *Methods Enzymol*. 1984;105:121-6.

24. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. *J Lab Clin Med*. 1967;70(1):158-69.

25. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. *Anal Biochem*. 1996;239(1):70-6.

26. Miri R, Saadati H, Ardi P, Firuzi O. Alterations in oxidative stress biomarkers associated with mild hyperlipidemia and smoking. *Food Chem Toxicol*. 2012;50(3-4):920-6.

27. Lavi CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. *J Am Coll Cardiol*. 2009;54(7):585-94.

28. Olga S, Ertrugul T, Nisli K, Omeroglu RE, Dindar A, Aydogan U. Fish oil supplementation improves left ventricular function in children with idiopathic dilated cardiomyopathy. *Congest Heart Fail*. 2007;13(6):308-12.

29. Egert S, Lindenmeier M, Harnack K, Krome K, Erbersdobler HF, Wahrburg U, et al. Margarines Fortified with α-Linolenic Acid, Eicosapentaenoic Acid, or Docosahexaenoic Acid Alter the Fatty Acid Composition of Erythrocytes but Do Not Affect the Antioxidant Status of Healthy Adults. *J Nutr*. 2012;142(9):1638-44.

30. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. *JAMA*. 2012;308(10):1024-33.

31. Mori TA, Woodman RJ, Burke V, Pudday IB, Croft KD, Beilin LJ. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. *Free Radic Biol Med*. 2003;35(7):772-81.

32. Petersson H, Risérus U, Monolose J, Gudset H, Tierney AC, Morange S, et al. Effects of dietary fat modification on oxidative stress and inflammatory markers in the LIPGENE study. *Br J Nutr*. 2010;104(9):1357-62.

33. Signori C, Dubroc C, Richie JP, Prokopczyk B, Demers LM, Hamilton C, et al. Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial. *Eur J Clin Nutr*. 2012;66(8):878-84.

34. Bouzidi N, Mekki K, Boukaddoum A, Dida N, Kaadou M. Effects of eicosapentaenoic fatty-acid supplementation on redox status in chronic renal failure patients with dyslipidemia. *J Ren Nutr*. 2010;20(5):321-8.